Table 1.
Enrichment of siMVPs in each drug selection cycle
| Name | Total sequenced clones | Selection cycle |
Potency (knockdown%) | |||
|---|---|---|---|---|---|---|
| 0th | 1st | 2nd | 3rd | |||
| 43 | 30 | 36 | 34 | |||
| siMVP586 | 5′-GGGGAAGAAUGGCUGGUCA-3′ | 0 | 5 | 21 | 24 | 87.3 |
| siMVP684 | 5′-GAAAAGACAGCCCUGCA-3′ | 0 | 2 | 5 | 7 | 77.3 |
| siMVP857 | 5′-UGCGUGAUUCUCGACCCUG-3′ | 0 | 0 | 2 | 1 | 72.1 |
| siMVP1270 | 5′-UGCCUCCCGGGUGGAGGAG-3′ | 0 | 0 | 3 | 2 | 75.8 |
The names of siMVPs were designated according to their positions in 1.3kb-MVP cDNA clone.
Only the sense strand is shown.
HeLa cells were transfected with 60 ng pEGFP, 1.2 ng pRLSV40 (Rluc) and 0.1nM siMVPs synthesized in vitro. Three independent assays each in triplicate were performed. The potency of siMVPs was calculated by the ratio of EGFP/Rluc against the control of unrelated siRNA (siHB1).